News
Keep up to date on the latest news from Recordati in our media section where you’ll find valuable insights into our operations and achievements. Explore our latest company announcements and financial news, as well as our dedication to bring a brighter future to people across the world.
Media
-
Business & Financial News
2024-04-24 19:18
RECORDATI: SUMMARY REPORT OF THE VOTES - ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 22.04.2024
2024, April 23
Press release (on "il Sole 24 Ore") - 2023 final payment dividend
2024-04-22 13:22
RECORDATI: THE SHAREHOLDERS’ MEETING APPROVES THE 2023 FINANCIAL STATEMENTS AND THE DIVIDEND OF € 1.20 PER SHARE (+4.3% vs 2022)
2024-04-11 19:15
RECORDATI: CONCLUSION OF THE SHARE BUY-BACK PROGRAM INITIATED ON 2nd OCTOBER 2023.
2024, March 29
Press release (on "il Sole 24 Ore") - Annual Financial Report, Non-Financial Statement and Corporate Governance Report 2023
2024-03-28 17:32
RECORDATI: DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS CALLED FOR 22.04.2024
2024-03-22 19:43
RECORDATI: DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS CALLED FOR 22.04.2024
2024, March 20
Press release (on "il Sole 24 Ore") - Extract of the call notice of the Ordinary Shareholders meeting 22.04.2024
2024-03-19 12:25
RECORDATI BOARD APPROVES THE 2023 ACCOUNTS, CONFIRMING STRONG PRELIMINARY RESULTS: REVENUE € 2,082.3M, EBITDA(1) € 769.6M, ADJUSTED NET INCOME(2) € 524.6M 2023 PROPOSED DIVIDEND € 1.20 (+4.3%)
2024-02-22 12:45
FY 2023 PRELIMINARY RESULTS AT TOP END OF GUIDANCE: REVENUE +12.4%, EBITDA +14.4%, ADJUSTED NET INCOME +10.8%. FY 2024 TARGETS REFLECT CONTINUED GROWTH ACROSS ALL KEY METRICS
2024-01-29 18:04
RECORDATI: 2024 CORPORATE EVENTS’ CALENDAR
2023, November 8
Press release (on "il Sole 24 Ore") - 2023 Interim Dividend Payment
2023-11-07 12:33
FIRST NINE MONTHS 2023 AHEAD OF PLAN: REVENUE +13.0%, EBITDA +15.4%, ADJUSTED NET INCOME +14.2%. 2025 REVENUE AND PROFITS EXPECTED TO EXCEED TARGETS SET IN FEBRUARY 2023
2023, October 16
RECORDATI APPOINTS MILAN ZDRAVKOVIC AS EXECUTIVE VICE PRESIDENT R&D
2023-09-29 18:03
RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION/PERFORMANCE SHARES PLANS
2023, August 1
Press release (on il Sole 24 Ore) - Interim Report First Half 2023
2023, July 31
RECORDATI: PUBLIC DISCLOSURE - INTERIM FINANCIAL STATEMENTS
2023-07-28 12:43
FIRST HALF 2023 RESULTS CONFIRM STRONG MOMENTUM OF THE GROUP: REVENUE +17.0%, EBITDA +21.3%, ADJUSTED NET INCOME +27.9%. RECENT TRANSACTION WITH GSK FURTHER STRENGTHENS SPC UROLOGY FRANCHISE
2023-07-20 17:48
RECORDATI: AGREEMENT FOR THE DISTRIBUTION OF AVODART® AND COMBODART® IN EUROPE
2023-06-27 18:11
RECORDATI: PERFORMANCE SHARE PLAN 2023-2025 ASSIGNMENT OF RIGHTS PROVIDED UNDER THE FIRST CYCLE
2023, May 19
LAUNCH OF THE 11TH EDITION OF THE ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH
2023-05-17 11:53
RECORDATI: MINUTES OF THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 21.04.2023
2023-05-11 13:48
FIRST QUARTER 2023 RESULTS: REVENUE +31.5%, EBITDA(1) +35.4%, ADJUSTED NET INCOME(2) +33.3%. FY 2023 GUIDANCE REVISED UPWARDS
2023, April 22
Press release (on "il Sole 24 Ore") - 2022 final payment dividend
2023, April 21
RECORDATI: SUMMARY REPORT OF THE VOTES - ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 21.04.2023
2023-04-21 17:12
RECORDATI: SUMMARY REPORT OF THE VOTES - ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 21.04.2023
2023, March 31
Press release (on "il Sole 24 Ore") - Annual Financial Report, Non-Financial Statement and Corporate Governance 2022,
2023-03-21 16:14
RECORDATI: PUBLICATION OF THE SLATES OF CANDIDATES FOR THE APPOINTMENT OF THE STATUTORY AUDITORS OF THE COMPANY PUBLICATION OF SLATES OF CANDIDATES FOR THE APPOINTMENT OF THE STATUTORY AUDITORS
2023-03-30 13:37
RECORDATI: DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 21.04.2023
2023-03-27 19:09
RECORDATI: FILING OF A SOLE SLATE FOR THE RENEWAL OF THE BOARD OF STATUTORY AUDITORS – EXTENSION OF THE DEADLINE AND REDUCTION BY HALF OF THE PARTICIPATION REQUIREMENTS FOR THE FILING
2023-03-22 18:23
RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 21.04.2023)
2023-03-16 12:34
RECORDATI BOARD APPROVES THE 2022 ACCOUNTS, CONFIRMING STRONG CONSOLIDATED FINANCIAL RESULTS: REVENUE +17.3%, EBITDA(1) +11.7%, ADJUSTED NET INCOME(2) +11.5% 2022 DIVIDEND € 1.15 (+4.5%),
2023, March 11
Press release (on "il Sole 24 Ore") - Extract of the call notice of the Ordinary Shareholders meeting 21.04.2023,
2023-03-10 12:53
RECORDATI: ORDINARY GENERAL MEETING OF SHAREHOLDERS CONVENED FOR 21 APRIL 2023, IN A SINGLE CALL. DOCUMENTS RELATING TO THE GENERAL MEETING.,
2023-02-21 12:59
RECORDATI: STRONG PRELIMINARY 2022 FINANCIAL RESULTS. REVENUE +17.3%, EBITDA(1) +11.7%, ADJUSTED NET INCOME(2) +11.5% 2023-2025 THREE-YEAR PLAN APPROVED; 2025 REVENUE TARGET BETWEEN € 2,250 AND € 2,350 MILLION,
2023-01-16 18:09
RECORDATI: 2023 CORPORATE EVENTS’ CALENDAR,
2022, November 9
Press release (on "il Sole 24 Ore") - 2022 Interim Dividend Payment,
2022-11-08 13:01
RECORDATI: RESULTS OF FIRST NINE MONTHS OF 2022 AHEAD OF EXPECTATIONS. REVENUE +19.1%, EBITDA(1) +15.2% AND ADJUSTED NET INCOME(2) +13.5%. FY 2022 RESULTS GUIDANCE REVISED UPWARDS,
2022, August 2
Press release (on il Sole 24 Ore) - Interim Report First Half 2022,
2022-08-02 18:06
RECORDATI: PUBLIC DISCLOSURE
2022-08-01 14:31
RECORDATI: PUBLIC DISCLOSURE
2022-07-28 13:28
RECORDATI FIRST HALF 2022 RESULTS: REVENUE +15.8%, EBITDA +11.5%, ADJUSTED NET INCOME +7.1%.,
2022-06-20 07:33
RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS,
2022, May 23
THE TENTH EDITION OF THE INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH ARRIGO RECORDATI COMES TO END,
2022-05-13 17:09
RECORDATI: MINUTES OF THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 29.04.2022
2022-05-10 11:56
RECORDATI: FIRST QUARTER 2022 RESULTS APPROVED, REVENUE +9.0%, EBITDA +8.7%. 2022 TARGETS CONFIRMED,
2022-05-03 12:45
RECORDATI: SUMMARY REPORT OF THE VOTES – ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 29.04.2022
2022, April 30
Press release (on "il Sole 24 Ore") - 2021 final payment dividend,
2022-04-29 12:44
RECORDATI: THE SHAREHOLDERS’ MEETING APPROVES THE 2021 FINANCIAL STATEMENTS. DIVIDEND OF € 1.10 PER SHARE (+4.8% vs 2020). THE NEW BOARD OF DIRECTORS HAS BEEN APPOINTED,
2022-04-08 16:52
RECORDATI – APPOINTMENT OF THE BOARD OF DIRECTORS: PUBLICATION OF THE SLATE AND OF THE RESOLUTION PROPOSALS FOR THE SHAREHOLDERS’ MEETING OF 29 APRIL 2022.,
2022-04-08 16:52
RECORDATI – APPOINTMENT OF THE BOARD OF DIRECTORS: PUBLICATION OF THE SLATE AND OF THE RESOLUTION PROPOSALS FOR THE SHAREHOLDERS’ MEETING OF 29 APRIL 2022.
2022, April 2
Press release (on "il Sole 24 Ore") - Annual Financial Report, Non-Financial Statement and Corporate Governance 2021,
2022-04-01 17:34
RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS’ 29.04.2022)
2022, March 19
Press release (on "il Sole 24 Ore") - Extract of the call notice of the Ordinary Shareholders meeting 29.04.2022,
2022-03-18 16:18
RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS’ 29.04.2022)
2022-03-17 17:44
RECORDATI: BOARD APPROVES THE 2021 ACCOUNTS. SALES € 1,580.1 MILLION (+9.1%), EBITDA(1) € 602.3 MILLION (+5.8%) ADJUSTED NET INCOME € 386.0 MILLION (+8.7%). 2021 DIVIDEND € 1.10 (+4.8%),
2022-03-16 18:03
RECORDATI COMPLETES THE ACQUISITION OF EUSA PHARMA (UK),
2022-02-24 13:18
RECORDATI: PRELIMINARY 2021 RESULTS IN LINE WITH TARGETS REVENUE +9.1%, EBITDA +5.8%, NET INCOME +8.7%,
2021-12-16 13:52
RECORDATI: KIM STRATTON CO-OPTED TO THE BOARD OF DIRECTORS AS A NON-EXECUTIVE AND NON-INDEPENDENT DIRECTOR,
2021-12-03 07:32
RECORDATI TO ACQUIRE EUSA PHARMA (UK) Ltd, A GLOBAL SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON RARE AND NICHE ONCOLOGY DISEASES,
2021-12-01 10:09
RECORDATI: ANDREA RECORDATI APPOINTED CHAIRMAN AND ROBERT KOREMANS APPOINTED CHIEF EXECUTIVE OFFICER,
2021-10-29 18:27
RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS RECORDATI SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS,
2021, October 29
Press release (on "il Sole 24 Ore") - 2021 Interim Dividend Payment,
2021-10-28 13:22
RECORDATI: 2021 FIRST NINE MONTHS RESULTS APPROVED. REVENUE +5.7%, EBITDA +2.1% AND NET INCOME +8.1%. THE RECOVERY BEGUN IN THE SECOND QUARTER CONTINUES,
2021-10-11 19:11
RECORDATI: RESIGNATION OF A NON-EXECUTIVE DIRECTOR,
2021-10-11 12:24
RECORDATI: 2022 CORPORATE EVENTS’ CALENDAR,
2021, July 30
Press release (on "il Sole 24 Ore") - Interim Report First Half 2021,
2022-07-30 15:50
RECORDATI: PUBLIC DISCLOSURE
2021-07-29 12:04
RECORDATI: FIRST HALF OF 2021 RESULTS APPROVED, REVENUE +1.4%, EBITDA -3.4%, NET INCOME +5.2%. RETURN TO GROWTH IN THE SECOND QUARTER,
2021-07-16 07:31
RECORDATI: Rob Koremans new Chief Executive Officer effective 1 December 2021, Andrea Recordati to be appointed as Chairman.,
2021, July 14
RECORDATI SUPPORTS THE FORESTAMI PROJECT,
2021-07-09 07:50
STRENGTHENING OF THE CORPORATE GOVERNANCE,
2021-05-05 17:17
RECORDATI: PUBLIC DISCLOSURE (MINUTES OF THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 20.04.2021)
2021, May 25
THE TENTH EDITION OF THE ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH HAS ANNOUNCED THE CALL FOR APPLICATIONS,
2021-05-06 13:12
RECORDATI: FIRST QUARTER 2021 RESULTS AND 2021-2023 THREE-YEAR PLAN APPROVED; 2023 REVENUE FORECAST BETWEEN €1,900 AND € 2,000 MILLION,
2021-04-28 09:37
RECORDATI TO PRESENT THE FIRST QUARTER 2021 RESULTS AND THE 2021-2023 STRATEGY AND OUTLOOK UPDATE,
2021-03-23 00:00
RECORDATI: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S ANNUAL MEETING REINFORCE THE EFFICACY AND SAFETY OF ISTURISA® (OSILODROSTAT) IN CUSHING’S DISEASE,
2021-04-22 12:22
RECORDATI: REGISTRATION WITH THE COMPANIES’ REGISTER OF THE MERGER DEED BY ABSORPTION OF ROSSINI INVESTIMENTI S.P.A. AND FIMEI S.P.A. INTO RECORDATI S.P.A. COMPLETED,
2021-04-22 11:25
RECORDATI: PUBLIC DISCLOSURE (SUMMARY REPORT OF THE VOTES - ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 20.04.2021)
2021, April 21
Press release (on "il Sole 24 Ore") - 2020 final payment dividend,
2021-04-20 12:47
RECORDATI: SHAREHOLDERS APPROVE THE 2020 ACCOUNTS. DIVIDEND € 1.05 PER SHARE (+5.0% vs 2019).,
2021-04-12 18:13
RECORDATI: THE MERGER DEED RELATING TO THE MERGER BY ABSORPTION OF ROSSINI INVESTIMENTI S.P.A. AND FIMEI S.P.A. INTO RECORDATI S.P.A. HAS BEEN EXECUTED,
2021, March 30
Press release (on "il Sole 24 Ore") - Annual Financial Report, Non-Financial Statement and Corporate Governance 2020,
2021-03-29 18:12
RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 20.04.2021)
2021, March 25
RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS’ 20.04.2021)
2021, March 24
RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED IN JAPAN,
2021, March 20
Press release (on "il Sole 24 Ore") - Extract of the call notice of the Ordinary Shareholders meeting 20.04.2021,
2021-03-19 18:59
RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 20.04.2021)
2021-03-18 16:42
RECORDATI: BOARD APPROVES THE 2020 ACCOUNTS. SALES € 1,448.9 MILLION (-2.2%), EBITDA € 569.3 MILLION (+4.7%) ADJUSTED NET INCOME € 410.4 MILLION (+7.3%). 2020 DIVIDEND € 1.05 (+ 5.0 %),
2021-02-22 18:25
RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS,
2021-02-22 12:58
RECORDATI: PRELIMINARY 2020 RESULTS CONFIRM CONTINUED GROWTH OF OPERATING AND NET INCOME. EBITDA +4.7% AND ADJ NET INCOME +7.3%,
2021-01-29 18:06
RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE AND OTHER COUNTRIES,
2021, January 26
RECORDATI: CARBAGLU receives U.S. FDA Approval for a New Indication to Treat Acute Hyperammonemia Associated with Propionic Acidemia and Methylmalonic Acidemia
2020-12-29 11:10
Public disclosure
2020-12-18 12:41
Public disclosure
2020-12-17 18:04
RECORDATI: MERGER BY ABSORPTION OF ROSSINI INVESTIMENTI S.P.A. AND FIMEI S.P.A. INTO RECORDATI S.P.A. APPROVED BY THE EXTRAORDINARY SHAREHOLDERS’ MEETING,
2020-12-09 18:04
RECORDATI: TAX PETITION FOR THE FRUITION OF ACE TAX BENEFITS DERIVING FROM THE REVERSE MERGER OBTAINED POSITIVE ANSWER,
2020-11-30 18:04
RECORDATI: MARKET AUTHORIZATION APPLICATION FOR ARS-1 (EPINEPHRINE NASAL SPRAY) ACCEPTED BY EUROPEAN MEDICINES AGENCY,
2021-11-30 00:00
RECORDATI: 2021 CORPORATE EVENTS’ CALENDAR,
2020, November 14
Press release - (on "Milano Finanza") - Extract of the call notice of the extraordinary general meeting of the shareholders 17.12.2020,
2020-11-13 17:42
Call to an extraordinary general meeting of the shareholders 17.12.2020 (Reverse Merger),
2021-03-25 15:04
RECORDATI: PUBLICATION OF DOCUMENTATION RELATED TO THE REVERSE MERGER BY ABSORPTION OF ROSSINI INVESTIMENTI S.p.A. AND FIMEI S.p.A. INTO RECORDATI S.p.A.
2020, October 30
Press release (on "il Sole 24 Ore") - 2020 Interim Dividend Payment,
2020-10-29 13:11
RECORDATI: PROFIT GROWTH IN THE FIRST NINE MONTHS OF 2020. REVENUES -0.6%, EBITDA +7.1%, ADJUSTED NET INCOME +12.3%,
2020-10-07 15:15
RECORDATI: PUBLICATION OF THE INFORMATION DOCUMENT RELATING TO MAJOR TRANSACTIONS WITH RELATED PARTIES
2021-05-25 15:04
RECORDATI: FILING OF THE MERGER PLAN RELATING TO THE MERGER BY ABSORPTION OF ROSSINI INVESTIMENTI S.p.A. AND FIMEI S.p.A. INTO RECORDATI S.p.A.
2020-10-01 18:07
RECORDATI: RECORDATI: MERGER BY ABSORPTION OF FIMEI S.P.A. AND ROSSINI INVESTIMENTI S.P.A. INTO RECORDATI S.P.A. APPROVED,
2020-09-21 00:00
RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION,
2020-08-25 00:00
RECORDATI: U.S. FDA APPROVES CYSTADROPS® (Cysteamine Ophthalmic Solution) 0.37%, A NEW PRACTICAL TREATMENT OPTION FOR THE OCULAR MANIFESTATIONS OF CYSTINOSIS,
2020-08-03 17:06
Public disclosure compliance
2020, July 31
Press release (on "il Sole 24 Ore") - Interim Report First Half 2020,
2020-07-30 13:53
RECORDATI ANNOUNCES POSITIVE FIRST HALF 2020 RESULTS. REVENUES +2.3%, EBITDA +11.4%, ADJUSTED NET INCOME +16.8%,
2020-07-17 13:53
ISTURISA® IS NOW AVAILABLE AS A MEDICAL TREATMENT FOR CUSHING'S SYNDROME IN GERMANY,
2020-06-17 13:52
RECORDATI: ISTURISA® (OSILODROSTAT) PHASE III LINC-4 TRIAL MEETS ITS PRIMARY ENDPOINT IN CUSHING’S DISEASE,
2020, June 2
Recordati Rare Diseases announces first European launch of Isturisa® (osilodrostat),
2020-05-27 12:30
Public disclosure
2020, May 27
RECORDATI RARE DISEASES INC. ANNOUNCES AVALABILITY OF ISTURISA® (OSILODROSTAT) IN THE UNITED STATES,
2020-05-07 12:35
RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2020. REVENUES +12.1%, EBITDA +20.1%,
2020, April 30
Press release (on "il Sole 24 Ore") - 2019 final payment dividend,
2020-04-03 17:50
Public disclosure
2020-04-29 12:11
RECORDATI SHAREHOLDERS APPROVE THE 2019 ACCOUNTS. DIVIDEND € 1.00 PER SHARE (+8.7% vs 2018),
2020-04-17 18:15
RECORDATI: PROPOSAL OF CANDIDATES FOR THE OFFICE OF DIRECTORS AND THEIR RELATIVE REMUNERATION PRESENTED BY THE MAJORITY SHAREHOLDER FIMEI SpA IN RELATION TO ITEM 2 ON THE SHAREHOLDERS’ MEETING AGENDA
2020-04-08 10:46
Public disclosure
2020-04-08 18:54
RECORDATI: PUBLICATION OF THE LIST OF CANDIDATES FOR THE APPOINTMENT OF THE STATUTORY AUDITORS OF THE COMPANY
2020, April 8
Recordati Rare Diseases is now the European Marketing Authorization holder of Isturisa® (osilodrostat) indicated for Adult patients with Endogenous Cushing’s Syndrome,
2020-04-04 18:28
RECORDATI: NOTICE PURSUANT TO ART. 144-OCTIES, PARAGRAPH 2 OF ISSUERS’ REGULATIONS
2020-03-30 12:24
Public disclosure
2020, March 26
RECORDATI SUBMITS NEW DRUG APPLICATION FOR ISTURISA® IN JAPAN,
2020, March 25
Press release (on "il Sole 24 Ore") - 2019 financial statements and corporate governance report,
2020-03-24 17:36
Public Disclosure
2020, March 20
Press release (on "il Sole 24 Ore") - Extract of the call notice of the Ordinary Shareholders meeting 29.04.2020,
2020-03-19 17:56
Public disclosure
2020-03-18 14:11
BOARD APPROVES THE 2019 ACCOUNTS. SALES € 1,481.8 MILLION (+9.6%), EBITDA € 544.0 MILLION (+9.0%). 2019 DIVIDEND € 1.00 (+8.7%).,
2020, March 18
RECORDATI CONTRIBUTES TO SUPPORT HOSPITALS AND PATIENTS IN THE FACE OF THE EPIDEMIOLOGIC EMERGENCY DUE TO COVID-19,
2020-03-12 19:59
RECORDATI: LAUNCH OF A NEW SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS,
2020-03-09 08:32
RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED IN THE U.S.,
2020-02-17 19:29
RECORDATI: LAUNCH OF A SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS,
2020-02-14 14:04
RECORDATI: PRELIMINARY 2019 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITS. SALES +9.6%. EBITDA +9.0%.,
2020, February 4
RECORDATI: CHANGE IN 2020 CORPORATE EVENTS’ CALENDAR,
2020-01-15 12:01
RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED,
2019-11-15 17:24
RECORDATI: CHMP ADOPTS POSITIVE OPINION FOR ISTURISA® (OSILODROSTAT),
2019, November 12
RECORDATI: 2020 CORPORATE EVENTS' CALENDAR,
2019, November 1
Press release - 2019 Interim dividend payment,
2019-10-31 12:58
RECORDATI ANNOUNCES GROWTH IN THE FIRST NINE MONTHS 2019. REVENUES +8.6%, EBITDA +7.8%, OPERATING INCOME +4.9%, NET INCOME +6.6%. INTERIM DIVIDEND € 0.48 (+6.7%).,
2019, October 29
INAUGURAZIONE DEL PADIGLIONE GIOVANNI RECORDATI ALL'OSPEDALE DEI BAMBINI VITTORE BUZZI,
2019-10-23 12:03
RECORDATI: ACQUISITION OF WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699) COMPLETED,
2019, September 5
ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH AWARDED TO ALBERTO AURICCHIO,
2019-07-31 19:15
Public disclosure compliance
2019, July 31
Sole24Ore - Notice Interim Report First Half 2019,
2019-07-30 13:10
RECORDATI ANNOUNCES GROWTH IN THE FIRST HALF 2019. REVENUES +6.8%, EBITDA +7.4%, NET INCOME +6.1%,
2019-07-12 20:15
RECORDATI TO ACQUIRE WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699),
2019, June 24
RECORDATI RARE DISEASES, A WORLDWIDE LEADER IN RARE DISEASES AND ORPHAN DRUGS,
2019-05-08 12:24
RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2019. NEW THREE YEAR BUSINESS PLAN APPROVED,
2019-05-03 16:47
Public Disclosure Compliance
2019-04-15 19:07
Public Disclosure Compliance
2019-04-15 09:06
RECORDATI TO MEET WITH THE FINANCIAL COMMUNITY,
2019, April 12
Press Release - Notice on 2018 final payment dividend,
2019-04-11 14:38
RECORDATI SHAREHOLDERS APPROVE THE 2018 ACCOUNTS. DIVIDEND € 0.92 PER SHARE (+8.2% vs 2017),
2019-03-20 18:57
Public Disclosure
2019-03-12 18:23
Public Disclosure
2019-03-08 10:45
Public Disclosure
2019, March 5
Sole24Ore - Extract of the call notice of the Ordinary Shareholders meeting - 11.04.2019,
2019, March 5
Press release - Notice of filing of 2018 Annual Report and Corporate Governance,
2019-03-05 19:23
Public Disclosure
2019-03-04 18:18
Public Disclosure
2019-02-28 15:08
RECORDATI: BOARD APPROVES THE 2018 ACCOUNTS. SALES € 1,352.2 MILLION (+5.0%), EBITDA € 499.1 MILLION (+9.8%), OPERATING INCOME € 442.2 MILLION (+8.8%) AND NET INCOME € 312.4 MILLION (+8.2%). 2018 DIVIDEND € 0.92 (+8.2%),
2019-02-11 12:54
RECORDATI: PRELIMINARY 2018 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITABILITY. SALES +5.0%, EBITDA +9.8%, OPERATING INCOME +8.8%, NET INCOME +8.2%.,
2019, February 6
Public Disclosure Compliance
2019, February 6
RECORDATI OBTAINS EXCLUSIVE LICENSE FOR JUXTAPID® IN JAPAN,
2019, February 5
RECORDATI: SHAREHOLDERS APPOINT THE NEW BOARD OF DIRECTORS. THE BOARD OF DIRECTORS APPOINTS FLEMMING ØRNSKOV AS CHAIRMAN AND CONFIRMS ANDREA RECORDATI AS CHIEF EXECUTIVE OFFICER,
2019, February 1
RECORDATI: TERMINATION BY MUTUAL AGREEMENT OF THE EMPLOYMENT RELATIONSHIP WITH ALBERTO RECORDATI
2019, January 28
RECORDATI: 2019 CORPORATE EVENTS' CALENDAR,
2019-01-11 17:30
RECORDATI: PUBLICATION OF THE SLATE OF CANDIDATES FOR THE APPOINTMENT OF DIRECTOR OF THE COMPANY BY A GROUP OF ASSET MANAGEMENT COMPANIES AND INSTITUTIONAL INVESTORS
2019-01-07 14:54
RECORDATI: PUBLICATION OF THE SLATE OF CANDIDATES FOR THE APPOINTMENT OF DIRECTOR OF THE COMPANY BY FIMEI S.P.A
2019, January 7
Press release on behalf of FIMEI S.p.A. - New Recordati Board members proposed by majority shareholder FIMEI, including Dr. Flemming Ørnskov as Chairman designate
2019, January 7
Press release on behalf of FIMEI S.p.A. - New Recordati Board members proposed by majority shareholder FIMEI, including Dr. Flemming Ørnskov as Chairman designate
2018, December 31
RECORDATI CLOSES ACQUISITION OF TONIPHARM S.A.S. IN FRANCE
2018-12-21 16:38
RECORDATI: EXPECTATIONS FOR 2018 CONFIRMED AND 2019 OBJECTIVES ANNOUNCED; APPROVAL OF THE ISSUER’S NOTICE PURSUANT TO ART. 103 PARA. 3 OF ITALIAN LEGISLATIVE DECREE 58/1998, WITH REFERENCE TO THE PUBLIC MANDATORY TENDER OFFER FOR THE TOTAL NUMBER OF ORDINARY SHARES OF RECORDATI S.P.A.
2018, December 21
RECORDATI ACQUIRES TONIPHARM S.A.S. IN FRANCE
2018, December 20
Sole24Ore: Call notice of the Ordinary Shareholders Meeting 5 February 2019,
2018, December 20
RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA®
2018-12-19 19:41
Public Disclosure
2018-12-12 20:13
Shareholders Agreements
2018-12-11 19:18
Publication of the abstract of the Shareholders' Agreements
2018-12-06 18:01
RECORDATI: RESIGNATION OF BOARD MEMBERS; CO-OPTION OF THREE NEW DIRECTORS; APPOINTMENT OF CHAIRMAN; AN ORDINARY GENERAL MEETING OF THE SHAREHOLDERS IS CONVENED TO APPOINT A NEW BOARD OF DIRECTORS
2018, December 5
RECORDATI RECEIVES ORPHAN DRUG DESIGNATION FOR ITS INVESTIGATIONAL TREATMENT FOR NEUROTROPHIC KERATITIS
2018, November 5
RECORDATI RECEIVES ORPHAN DRUG DESIGNATION FOR ITS INVESTIGATIONAL TREATMENT FOR MSUD
2018, October 31
Notice: 2018 interim dividend payment,
2018-10-30 13:21
RECORDATI ANNOUNCES SALES AND MARGIN GROWTH IN THE FIRST NINE MONTHS 2018. REVENUES +5.1%, EBITDA +11.1%, OPERATING INCOME +9.6%, NET INCOME +8.2%. INTERIM DIVIDEND € 0.45 (+7.1%)
2018, September 12
THE NINTH EDITION OF THE INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH ARRIGO RECORDATI HAS ANNOUNCED THE CALL FOR NOMINATIONS
2018-08-03 15:08
Stock Options Granted
2018, July 28
Sole 24Ore: Notice Interim Report First Half 2018,
2018-07-26 12:24
RECORDATI ANNOUNCES SALES AND MARGIN GROWTH IN THE FIRST HALF 2018. REVENUES +6.9%, OPERATING INCOME +14.1%, NET INCOME +11.7%
2018-07-04 21:38
Shareholders Agreements
2018, July 4
SHAREHOLDERS AGREEMENTS,
2018-07-02 18:01
CVC AGREES TO ACQUIRE FIMEI S.P.A.
2018-06-29 20:10
CVC AGREES TO ACQUIRE FIMEI S.P.A.
2018, June 29
CVC Fund VII Acquires Controlling Stake in Recordati S.p.A.
2018, June 11
RECORDATI ACQUIRES NATURAL POINT S.R.L. IN ITALY
2018-05-09 15:48
Public Disclosure Compliance (shareholders' meeting minutes dated 18.04.18)
2018-05-08 11:25
RECORDATI ANNOUNCES SALES AND MARGIN GROWTH IN THE FIRST QUARTER 2018. REVENUES +7.2%, OPERATING INCOME +12.4%, NET INCOME +10.3%
2018, April 19
Sole24Ore - Notice of final dividend payment,
2018, April 18
Public Disclosure Compliance
2018, April 9
RECORDATI ACQUIRES INTERNATIONAL RIGHTS TO CYSTAGON® FROM MYLAN
2018-04-08 12:47
RECORDATI: SHAREHOLDERS APPROVE THE 2017 ACCOUNTS. DIVIDEND € 0.85 PER SHARE (+21.4% vs 2016)
2018-03-27 19:45
Public disclosure compliance
2018-03-19 17:23
Pubblic Disclosure
2018, March 16
Sole24Ore - Call notice of the Ordinary Shareholders meeting - 18.04.2018,
2018-03-16 19:18
Public Disclosure
2018, March 16
Sole24Ore - Notice of filing of 2017 Annual Report and Corporate Governance,
2018-03-15 12:14
RECORDATI: BOARD APPROVES THE 2017 ACCOUNTS. SALES € 1,288.1 MILLION (+11.6%), OPERATING INCOME € 406.5 MILLION (+24.1%) AND NET INCOME € 288.8 MILLION (+21.6%). 2017 DIVIDEND € 0.85 (+21.4%)
2018-02-08 12:23
RECORDATI: PRELIMINARY 2017 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITABILITY. SALES +11.6%, OPERATING INCOME +24.1%, NET INCOME +21.6%
2017, December 18
RECORDATI ACQUIRES TRANSIPEG®, TRANSIPEGLIB® AND COLOPEG® FOR THE FRENCH MARKET,
2017, November 29
RECORDATI: 2018 CORPORATE EVENTS' CALENDAR,
2017, October 27
Notice: 2017 INTERIM DIVIDEND PAYMENT,
2017-10-26 11:51
RECORDATI: EXCELLENT RESULTS IN THE FIRST NINE MONTHS 2017. CONTINUED GROWTH IN SALES +11.8%, OPERATING INCOME +21.8%, NET INCOME +20.6%. INTERIM DIVIDEND € 0.42 (+20%),
2017, July 28
Notice - Half Yearly Financial Report at 30 June 2017,
2017-07-27 11:14
RECORDATI: VERY GOOD RESULTS AGAIN IN THE FIRST HALF 2017. CONTINUED GROWTH IN SALES +10.7%, OPERATING INCOME +19.4%, NET INCOME +19.8%.,
2017-07-19 18:13
RECORDATI: THE EUROPEAN COMMISSION APPROVES REAGILA® (CARIPRAZINE) FOR THE TREATMENT OF SCHIZOPHRENIA,
2017, July 7
Recordati Rare Diseases Introduces New PANHEMATIN® (Hemin for Injection) Dosage Strength for Treatment of Acute Intermittent Porphyria (AIP),
2017-07-03 08:01
RECORDATI: ACQUISITION OF RIGHTS TO ASTRAZENECA'S METOPROLOL BASED TREATMENTS IN EUROPE COMPLETED,
2017, June 16
RECORDATI LICENSES AN INNOVATIVE TREATMENT FOR NEUROTROPHIC KERATITIS,
2017-05-22 08:01
RECORDATI ACQUIRES RIGHTS TO ASTRAZENECA’S METOPROLOL BASED TREATMENTS IN EUROPE,
2017, May 19
European CHMP Issues Positive Opinion for Cariprazine for the Treatment of Schizophrenia,
2017-05-10 19:13
Public disclosure compliance,
2017-05-04 12:49
RECORDATI: EXCELLENT RESULTS IN THE FIRST QUARTER 2017. CONTINUED GROWTH IN SALES +13.1%, OPERATING INCOME +19.0%, NET INCOME +19.9%,
2017-04-19 00:00
Recordati establishes Canadian presence with launch of Recordati Rare Diseases Canada Inc.,
2017-04-13 00:00
Recordati Rare Diseases Inc. Acquires North American Marketing Rights to CYSTADANE®,
2017, April 12
Notice of 2016 final dividend payment,
2017-04-11 14:11
RECORDATI: SHAREHOLDERS APPROVE THE 2016 ACCOUNTS. DIVIDEND € 0.70 PER SHARE (+16.7% vs 2015),
2017-04-07 18:35
BoD resolution approving the merger registered with Companies Register
2017-04-05 11:03
BoD approves the merger of Recordati SA Chemical and Pharmaceutical Company in Recordati SPA
2017-03-20 19:09
RECORDATI: PUBLICATION OF LISTS OF CANDIDATES FOR THE APPOINTMENT OF DIRECTOR AND STATUTORY AUDITOR OF THE COMPANY
2017-03-17 16:56
Public disclosure
2017-03-17 18:19
RECORDATI: NOTICE PURSUANT TO ART. 144-OCTIES, PARAGRAPH 2 OF ISSUERS’ REGULATIONS
2017-03-19 17:47
Public disclosure
2017, March 2
Notice of filing of 2016 Annual Report and merger notice to shareholders,
2017-03-01 12:38
RECORDATI: BOARD APPROVES THE 2016 ACCOUNTS. SALES € 1,153.9 MILLION (+10.1%), OPERATING INCOME € 327.4 MILLION (+17.6%) AND NET INCOME € 237.4 MILLION (+19.4%). 2016 DIVIDEND € 0.70 (+16.7%),
2017-03-01 17:40
Call notice of Ordinary and Extraordinary Shareholders Meeting 11 April 2017,
2017-03-01 19:26
Public disclosure
2017-02-27 12:59
RECORDATI: SIGNS AN EXCLUSIVE LICENSE AGREEMENT WITH THE MEYER HOSPITAL IN FLORENCE,
2017-02-09 12:23
RECORDATI: PRELIMINARY 2016 RESULTS CONFIRM CONTINUED GROWTH OF REVENUES AND PROFITABILITY. NEW THREE YEAR BUSINESS PLAN PRESENTED,
2017-02-01 08:35
RECORDATI TO MEET WITH THE FINANCIAL COMMUNITY AND SPECIALIZED PRESS IN MILAN,
2017, January 27
RECORDATI ANNOUNCES MARKETING APPROVAL FOR CYSTADROPS®,
2016, December 14
UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM
2016, December 14
RECORDATI: 2017 CORPORATE EVENTS’ CALENDAR and DISCLOSURE OF QUARTERLY REPORTS,
2016, December 6
UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM
2016, December 1
UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM
2016, November 24
UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM
2016, November 17
UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM
2016, November 15
ERYTECH ANNOUNCES WITHDRAWAL OF ITS EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR GRASPA FOR ACUTE LYMPHOBASTIC LEUKEMIA AND PREPARES FOR RESUBMISSION,
2016, November 10
UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM
2016, October 28
Notice: 2016 INTERIM DIVIDEND PAYMENT,
2016, October 27
RECORDATI: EXCELLENT RESULTS IN THE FIRST NINE MONTHS 2016. CONTINUED GROWTH IN SALES +9.9%, OPERATING INCOME +18.5%, NET INCOME +19.5%,
2016, October 2
Recordati initiates a share buy-back program
2016, August 16
RECORDATI ANNOUNCES THAT ITS CHAIRMAN AND CEO GIOVANNI RECORDATI PASSED AWAY,
2016, August 16
RECORDATI: ALBERTO RECORDATI APPOINTED CHAIRMAN; ANDREA RECORDATI APPOINTED VICE CHAIRMAN AND CHIEF EXECUTIVE OFFICER,
2016, August 2
RECORDATI AND RICHTER SIGNED A LICENSE AGREEMENT FOR MARKETING CARIPRAZINE IN WESTERN EUROPE,
2016, July 29
Notice - Half Yearly Financial Report at 30 June 2016,
2016, July 28
RECORDATI: EXCELLENT RESULTS IN THE FIRST HALF 2016. CONTINUED GROWTH IN SALES +9.1%, OPERATING INCOME +17.2%, NET INCOME +18.9%,
2016, July 14
RECORDATI ACQUIRES THE SWISS PHARMACEUTICAL COMPANY PRO FARMA,
2016, May 31
RECORDATI ACQUIRES THE ITALIAN PHARMACEUTICAL COMPANY ITALCHIMICI,
2016, May 5
RECORDATI: EXCELLENT RESULTS IN THE FIRST QUARTER 2016. SALES +9.6%, OPERATING INCOME +22.7%, NET INCOME +26.0%,
2016, May 2
Public Disclosure - Minutes SHM 13.4.2016
2016, April 14
Notice of 2015 final dividend payment,
2016, April 13
RECORDATI SHAREHOLDERS APPROVE THE 2015 ACCOUNTS. DIVIDEND € 0.60 PER SHARE (+20.0% vs 2014),
2016, March 21
PUBLIC DISCLOSURE
2016, March 15
PUBLIC DISCLOSURE
2016, March 9
Notice of filing of the 2015 Annual Report,
2016, March 8
SHGM Call notice 13 April 2016,
2016, March 8
RECORDATI: BOARD APPROVES THE 2015 ACCOUNTS. SALES € 1,047.7 MILLION (+6.1%), OPERATING INCOME € 278.5 MILLION (+20.6%) AND NET INCOME € 198.8 MILLION (+23.3%). 2015 DIVIDEND € 0.60 (+20.0%),
2016, February 29
RARE DISEASE DAY,
2016, February 12
Update on the execution of the share buy-back program
2016, February 11
RECORDATI PRELIMINARY 2015 RESULTS: REVENUE GROWTH AND FURTHER MARGIN IMPROVEMENT, SALES +6.1%, OPERATING INCOME +20.6% AND NET INCOME +23.3%
2015, November 20
2016 Corporate events' calendar,
2015, October 29
First nine months 2015 and 2015 interim dividend payment 2015,
2015, October 28
RECORDATI REPORTS SALES +5.7%, OPERATING INCOME +18.1% AND NET INCOME +23.0% IN THE FIRST NINE MONTHS 2015. THE INTERNATIONAL BUSINESS GROWS BY 8.8%,
2015, October 15
Update on the execution of the share buy-back program
2015, October 6
Update on the execution of the share buy-back program
2015, September 14
ERYTECH submits EMA Marketing Authorization,
2015, September 8
ORPHAN EUROPE Announces that Health Canada has Granted Market Authorization for Carbaglu® (carglumic acid),
2015, July 30
Notice of filing of yearly financial report 2015 of filing - half - yearly financial report 2015,
2015, July 29
RECORDATI REPORTS SALES +6.2%, OPERATING INCOME +19.2% AND NET INCOME +24.3% IN THE FIRST HALF 2015 THANKS TO ITS INTERNATIONAL BUSINESS,
2015, June 13
ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH AWARDED TO JOHN J. V. MCMURRAY AND SALIM YUSUF,
2015, May 15
Update on the execution of the share buy-back program
2015, May 6
Notice of filing of First Quarter 2015,
2015, May 5
RECORDATI: SALES GROWTH AND FURTHER MARGIN IMPROVEMENT IN THE FIRST QUARTER 2015. SALES +5.9%, OPERATING INCOME +18.1%, NET INCOME +21.5%,
2015, April 30
Public disclosure compliance - Minutes of the Shareholders' meeting 15.4.2015
2015, April 30
Recordati initiates a share buy-back program
2015, April 16
Notice of 2014 final dividend payment,
2015-04-15 18:07
RECORDATI: RECORDATI SHAREHOLDERS APPROVE THE 2014 ACCOUNTS. DIVIDEND € 0.50 PER SHARE (+51.5% vs 2013),
2015, March 18
Public Disclosure Compliance
2015, March 5
Avviso integrale di convocazione dell’Assemblea degli Azionisti del 15 aprile 2015,
2015, March 5
SHGM Call notice,
2015, March 5
Notice of filing of the 2014 Annual Report,
2015, March 4
RECORDATI; BOARD APPROVES THE 2014 ACCOUNTS. REVENUES € 987.4 MILLION (+4.9%), OPERATING INCOME € 231.0 MILLION (+18.2%), NET INCOME € 161.2 MILLION (+20.6%). 2014 DIVIDEND € 0.50 (+51.5%),
2015-02-12 12:03
RECORDATI: PRELIMINARY 2014 RESULTS: REVENUE GROWTH AND SIGNIFICANT MARGIN IMPROVEMENT, SALES +4.9%, OPERATING INCOME +18.2% AND NET INCOME +20.6%,
2015, January 16
RECORDATI: CHANGE TO 2015 CORPORATE EVENTS CALENDAR
2014, November 28
Recordati: 2015 Corporate Events’ Calendar,
2014, October 28
Notice of filing of First nine months 2014,
2014, October 28
Revenue growth and significant margin improvement in first nine months 2014 results. Sales +5.7%, operating income +21.6% and net income +22.2%,
2014, October 9
Recordati initiates a share buy-back program,
2014, September 30
ERYTECH reports positive top-line Phase III results from clinical study with GRASPA® in Acute Lymphoblastic Leukemia,
2014, September 22
Recordati: public disclosure compliance
2014, September 16
Recordati obtains license to new treatment for premature ejaculation from Plethora,
2014, August 30
The eighth edition of the Arrigo Recordati International Prize for Scientific Research issues the call for nominations,
2014, August 1
Recordati: public disclosure compliance
2014, July 29
Notice of filing of First Half 2014,
2014, July 29
Recordati reports excellent results in the first half 2014. Sales +6.3%, operating income +18.8% and net income +18.1,
2014, July 3
Recordati: Carbaglu® receives orphan drug designation in the U.S. For organic acidemias,
2014, May 26
Recordati finalizes the second tranche of its acquisition of Opalia Pharma in Tunisia,
2014-04-17 14:11
Recordati: Shareholders approve the 2013 accounts. Dividend € 0.33 per share.,
2014, May 9
Recordati: public disclosure compliance
2014, May 6
Notice of filing of First Quarter 2014,
2014-05-06 07:33
Recordati: sales growth and significant margin improvement in the first quarter 2014 (sales +6.5%, operating income +18.1%, net income +13.2%),
2014, April 18
Notice of 2013 final dividend payment,
2014, April 11
Recordati receives the special Award "Finance for Growth",
2014, March 27
Recordati: publication of lists of candidates for the appointment of Directors and Statutory Auditors of the company
2014, March 24
Recordati: notice pursuant to art. 144-octies, paragraph 2 of issuers' regulations
2014, March 21
Recordati: public disclosure compliance
2014, March 14
Recordati: public disclosure compliance
2014, March 7
Notice of filing of the 2013 Annual Report,
2014, March 6
Recordati: Board approves the2013 accounts. Revenue € 941.6 million (+13.7%), operating income € 195.4 million (+17.0%), net income € 133.7 million (+12.8%). 2013 dividend € 0.33 (+10.0%),
2014, February 26
The European Organisation for Rare Diseases awards Orphan Europe for exceptional contribution to reducing the impact of rare diseases on people's lives,
2014, February 11
Recordati: preliminary 2013 results show significant growth. Sales +13.7%, EBIT +17.0%, net income +12.8%. A productive year for investments,
2014, February 10
Recordati obtains Vitaros® license from Apricus Biosciences,
2014, January 16
Recordati Board of Directors approves 2014 objectives
2013, December 17
Recordati: 2014 corporate events' calendar,
2013, October 31
Interim Report - First nine months 2013 and 2013 interim dividend payment,
2013, October 31
Recordati finalizes the first tranche of its acquisition of Opalia Pharma in Tunisia,
2013, October 30
Recordati reports significant growth in the first nine months 2013. Sales +13.2%, operating income +12.0% and net income +9.0%. Interim dividend € 0.22 per share,
2013, October 21
Recordati finalizes its acquisition of Laboratorios Casen Fleet in Spain,
2013, September 23
Recordati: Andrea Recordati appointed Chief Operating Officer (COO),
2013, September 17
Recordati: update on the execution of the share buy-back program
2013, September 9
Recordati acquires the Spanish pharmaceutical company Laboratorios Casen Fleet,
2013, September 6
Recordati: update on the execution of the share buy-back program
2013, July 26
Notice of filing of First Half 2013,
2013, July 25
Recordati reports excellent results in the first half 2013. Sales +13.8%, operating income +13.8% and net income +11.1%,
2013, July 24
Recordati: update on the execution of the share buy-back program
2013, July 24
Recordati acquires the Tunisian pharmaceutical company Opalia Pharma,
2013, July 3
Recordati: update on the execution of the share buy-back program
2013, June 24
Recordati: update on the execution of the share buy-back program
2013, June 15
Arrigo Recordati International Prize for Scientific Research awarded to Filippo Crea,
2013, June 14
Recordati: update on the execution of the share buy-back program
2013, June 6
Recordati: update on the execution of the share buy-back program
2013, May 29
Recordati: update on the execution of the share buy-back program
2013, May 21
Recordati: update on the execution of the share buy-back program
2013, May 10
Notice of filing of First Quarter 2013,
2013-05-09 12:01
Recordati: initiates a share buy-back program,
2013, May 9
Recordati: significant sales and earnings growth in the first quarter 2013 (sales +11.4%, net income +11.8%) thanks to the international business (+16.1%),
2013, May 7
Recordati: Public disclosure compliance - Minutes SHGM 17.4.2013
2013, April 18
Notice of 2012 final dividend payment,
2013, April 17
Recordati: shareholders approve the 2012 accounts. Dividend € 0.30 per share,
2013, March 22
Recordati: public disclosure compliance - Publication Remuneration report
2013, March 15
Recordat: public disclosure compliance – Publications of the Directors’ reports
2013, March 15
Shareholders' Meeting Call Notice,
2013, March 15
Shareholders' Meeting Call Notice,
2013, March 14
Recordati: Board approves a supplement to the agenda of the annual meeting of shareholders
2013, March 14
Recordati: public disclosure compliance
2013, March 8
Notice of filing of the 2012 Annual Report,
2013, March 7
Recordati: Board approves the 2012 accounts. Revenue € 828.3 million (+8.7%), operating income € 167.0 million (+2.1%), net income € 118.5 million (+1.8%). 2012 dividend € 0.30,
2013, February 12
Recordati: positive preliminary 2012 results. Sales +8.7%, EBIT +2.1%, net income +1.8%. A productive year for investments,
2013-02-04 08:35
Recordati to meet with the financial community and specialized press in Milan,
2013, January 31
Recordati: update on the execution of the share buy-back program
2013, January 21
Recordati finalizes its acquisition of a portfolio of products in the USA
2012, May 8
Recordati: good first quarter 2012 results (revenue +11.0%, net income +7.5%) thanks to the growth of the international business (+14.5%),
-
Announcements
2024-04-24 19:18
RECORDATI: SUMMARY REPORT OF THE VOTES - ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 22.04.2024
2024, April 23
Press release (on "il Sole 24 Ore") - 2023 final payment dividend
2024-04-22 13:22
RECORDATI: THE SHAREHOLDERS’ MEETING APPROVES THE 2023 FINANCIAL STATEMENTS AND THE DIVIDEND OF € 1.20 PER SHARE (+4.3% vs 2022)
2024-04-11 19:15
RECORDATI: CONCLUSION OF THE SHARE BUY-BACK PROGRAM INITIATED ON 2nd OCTOBER 2023.
2024, March 29
Press release (on "il Sole 24 Ore") - Annual Financial Report, Non-Financial Statement and Corporate Governance Report 2023
2024-03-28 17:32
RECORDATI: DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS CALLED FOR 22.04.2024
2024-03-22 19:43
RECORDATI: DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS CALLED FOR 22.04.2024
2024, March 20
Press release (on "il Sole 24 Ore") - Extract of the call notice of the Ordinary Shareholders meeting 22.04.2024
2024-03-19 12:25
RECORDATI BOARD APPROVES THE 2023 ACCOUNTS, CONFIRMING STRONG PRELIMINARY RESULTS: REVENUE € 2,082.3M, EBITDA(1) € 769.6M, ADJUSTED NET INCOME(2) € 524.6M 2023 PROPOSED DIVIDEND € 1.20 (+4.3%)
2024-02-22 12:45
FY 2023 PRELIMINARY RESULTS AT TOP END OF GUIDANCE: REVENUE +12.4%, EBITDA +14.4%, ADJUSTED NET INCOME +10.8%. FY 2024 TARGETS REFLECT CONTINUED GROWTH ACROSS ALL KEY METRICS
2024-01-29 18:04
RECORDATI: 2024 CORPORATE EVENTS’ CALENDAR
2023, November 8
Press release (on "il Sole 24 Ore") - 2023 Interim Dividend Payment
2023-11-07 12:33
FIRST NINE MONTHS 2023 AHEAD OF PLAN: REVENUE +13.0%, EBITDA +15.4%, ADJUSTED NET INCOME +14.2%. 2025 REVENUE AND PROFITS EXPECTED TO EXCEED TARGETS SET IN FEBRUARY 2023
2023, October 16
RECORDATI APPOINTS MILAN ZDRAVKOVIC AS EXECUTIVE VICE PRESIDENT R&D
2023-09-29 18:03
RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION/PERFORMANCE SHARES PLANS
2023, August 1
Press release (on il Sole 24 Ore) - Interim Report First Half 2023
2023, July 31
RECORDATI: PUBLIC DISCLOSURE - INTERIM FINANCIAL STATEMENTS
2023-07-28 12:43
FIRST HALF 2023 RESULTS CONFIRM STRONG MOMENTUM OF THE GROUP: REVENUE +17.0%, EBITDA +21.3%, ADJUSTED NET INCOME +27.9%. RECENT TRANSACTION WITH GSK FURTHER STRENGTHENS SPC UROLOGY FRANCHISE
2023-07-20 17:48
RECORDATI: AGREEMENT FOR THE DISTRIBUTION OF AVODART® AND COMBODART® IN EUROPE
2023-06-27 18:11
RECORDATI: PERFORMANCE SHARE PLAN 2023-2025 ASSIGNMENT OF RIGHTS PROVIDED UNDER THE FIRST CYCLE
2023, May 19
LAUNCH OF THE 11TH EDITION OF THE ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH
2023-05-17 11:53
RECORDATI: MINUTES OF THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 21.04.2023
2023-05-11 13:48
FIRST QUARTER 2023 RESULTS: REVENUE +31.5%, EBITDA(1) +35.4%, ADJUSTED NET INCOME(2) +33.3%. FY 2023 GUIDANCE REVISED UPWARDS
2023, April 22
Press release (on "il Sole 24 Ore") - 2022 final payment dividend
2023, April 21
RECORDATI: SUMMARY REPORT OF THE VOTES - ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 21.04.2023
2023-04-21 17:12
RECORDATI: SUMMARY REPORT OF THE VOTES - ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 21.04.2023
2023, March 31
Press release (on "il Sole 24 Ore") - Annual Financial Report, Non-Financial Statement and Corporate Governance 2022,
2023-03-21 16:14
RECORDATI: PUBLICATION OF THE SLATES OF CANDIDATES FOR THE APPOINTMENT OF THE STATUTORY AUDITORS OF THE COMPANY PUBLICATION OF SLATES OF CANDIDATES FOR THE APPOINTMENT OF THE STATUTORY AUDITORS
2023-03-30 13:37
RECORDATI: DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 21.04.2023
2023-03-27 19:09
RECORDATI: FILING OF A SOLE SLATE FOR THE RENEWAL OF THE BOARD OF STATUTORY AUDITORS – EXTENSION OF THE DEADLINE AND REDUCTION BY HALF OF THE PARTICIPATION REQUIREMENTS FOR THE FILING
2023-03-22 18:23
RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 21.04.2023)
2023-03-16 12:34
RECORDATI BOARD APPROVES THE 2022 ACCOUNTS, CONFIRMING STRONG CONSOLIDATED FINANCIAL RESULTS: REVENUE +17.3%, EBITDA(1) +11.7%, ADJUSTED NET INCOME(2) +11.5% 2022 DIVIDEND € 1.15 (+4.5%),
2023, March 11
Press release (on "il Sole 24 Ore") - Extract of the call notice of the Ordinary Shareholders meeting 21.04.2023,
2023-03-10 12:53
RECORDATI: ORDINARY GENERAL MEETING OF SHAREHOLDERS CONVENED FOR 21 APRIL 2023, IN A SINGLE CALL. DOCUMENTS RELATING TO THE GENERAL MEETING.,
2023-02-21 12:59
RECORDATI: STRONG PRELIMINARY 2022 FINANCIAL RESULTS. REVENUE +17.3%, EBITDA(1) +11.7%, ADJUSTED NET INCOME(2) +11.5% 2023-2025 THREE-YEAR PLAN APPROVED; 2025 REVENUE TARGET BETWEEN € 2,250 AND € 2,350 MILLION,
2023-01-16 18:09
RECORDATI: 2023 CORPORATE EVENTS’ CALENDAR,
2022, November 9
Press release (on "il Sole 24 Ore") - 2022 Interim Dividend Payment,
2022-11-08 13:01
RECORDATI: RESULTS OF FIRST NINE MONTHS OF 2022 AHEAD OF EXPECTATIONS. REVENUE +19.1%, EBITDA(1) +15.2% AND ADJUSTED NET INCOME(2) +13.5%. FY 2022 RESULTS GUIDANCE REVISED UPWARDS,
2022, August 2
Press release (on il Sole 24 Ore) - Interim Report First Half 2022,
2022-08-02 18:06
RECORDATI: PUBLIC DISCLOSURE
2022-08-01 14:31
RECORDATI: PUBLIC DISCLOSURE
2022-07-28 13:28
RECORDATI FIRST HALF 2022 RESULTS: REVENUE +15.8%, EBITDA +11.5%, ADJUSTED NET INCOME +7.1%.,
2022-06-20 07:33
RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS,
2022, May 23
THE TENTH EDITION OF THE INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH ARRIGO RECORDATI COMES TO END,
2022-05-13 17:09
RECORDATI: MINUTES OF THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 29.04.2022
2022-05-10 11:56
RECORDATI: FIRST QUARTER 2022 RESULTS APPROVED, REVENUE +9.0%, EBITDA +8.7%. 2022 TARGETS CONFIRMED,
2022-05-03 12:45
RECORDATI: SUMMARY REPORT OF THE VOTES – ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 29.04.2022
2022, April 30
Press release (on "il Sole 24 Ore") - 2021 final payment dividend,
2022-04-29 12:44
RECORDATI: THE SHAREHOLDERS’ MEETING APPROVES THE 2021 FINANCIAL STATEMENTS. DIVIDEND OF € 1.10 PER SHARE (+4.8% vs 2020). THE NEW BOARD OF DIRECTORS HAS BEEN APPOINTED,
2022-04-08 16:52
RECORDATI – APPOINTMENT OF THE BOARD OF DIRECTORS: PUBLICATION OF THE SLATE AND OF THE RESOLUTION PROPOSALS FOR THE SHAREHOLDERS’ MEETING OF 29 APRIL 2022.,
2022-04-08 16:52
RECORDATI – APPOINTMENT OF THE BOARD OF DIRECTORS: PUBLICATION OF THE SLATE AND OF THE RESOLUTION PROPOSALS FOR THE SHAREHOLDERS’ MEETING OF 29 APRIL 2022.
2022, April 2
Press release (on "il Sole 24 Ore") - Annual Financial Report, Non-Financial Statement and Corporate Governance 2021,
2022-04-01 17:34
RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS’ 29.04.2022)
2022, March 19
Press release (on "il Sole 24 Ore") - Extract of the call notice of the Ordinary Shareholders meeting 29.04.2022,
2022-03-18 16:18
RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS’ 29.04.2022)
2022-03-17 17:44
RECORDATI: BOARD APPROVES THE 2021 ACCOUNTS. SALES € 1,580.1 MILLION (+9.1%), EBITDA(1) € 602.3 MILLION (+5.8%) ADJUSTED NET INCOME € 386.0 MILLION (+8.7%). 2021 DIVIDEND € 1.10 (+4.8%),
2022-03-16 18:03
RECORDATI COMPLETES THE ACQUISITION OF EUSA PHARMA (UK),
2022-02-24 13:18
RECORDATI: PRELIMINARY 2021 RESULTS IN LINE WITH TARGETS REVENUE +9.1%, EBITDA +5.8%, NET INCOME +8.7%,
2021-12-16 13:52
RECORDATI: KIM STRATTON CO-OPTED TO THE BOARD OF DIRECTORS AS A NON-EXECUTIVE AND NON-INDEPENDENT DIRECTOR,
2021-12-03 07:32
RECORDATI TO ACQUIRE EUSA PHARMA (UK) Ltd, A GLOBAL SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON RARE AND NICHE ONCOLOGY DISEASES,
2021-12-01 10:09
RECORDATI: ANDREA RECORDATI APPOINTED CHAIRMAN AND ROBERT KOREMANS APPOINTED CHIEF EXECUTIVE OFFICER,
2021-10-29 18:27
RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS RECORDATI SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS,
2021, October 29
Press release (on "il Sole 24 Ore") - 2021 Interim Dividend Payment,
2021-10-28 13:22
RECORDATI: 2021 FIRST NINE MONTHS RESULTS APPROVED. REVENUE +5.7%, EBITDA +2.1% AND NET INCOME +8.1%. THE RECOVERY BEGUN IN THE SECOND QUARTER CONTINUES,
2021-10-11 19:11
RECORDATI: RESIGNATION OF A NON-EXECUTIVE DIRECTOR,
2021-10-11 12:24
RECORDATI: 2022 CORPORATE EVENTS’ CALENDAR,
2021, July 30
Press release (on "il Sole 24 Ore") - Interim Report First Half 2021,
2022-07-30 15:50
RECORDATI: PUBLIC DISCLOSURE
2021-07-29 12:04
RECORDATI: FIRST HALF OF 2021 RESULTS APPROVED, REVENUE +1.4%, EBITDA -3.4%, NET INCOME +5.2%. RETURN TO GROWTH IN THE SECOND QUARTER,
2021-07-16 07:31
RECORDATI: Rob Koremans new Chief Executive Officer effective 1 December 2021, Andrea Recordati to be appointed as Chairman.,
2021, July 14
RECORDATI SUPPORTS THE FORESTAMI PROJECT,
2021-07-09 07:50
STRENGTHENING OF THE CORPORATE GOVERNANCE,
2021-05-05 17:17
RECORDATI: PUBLIC DISCLOSURE (MINUTES OF THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 20.04.2021)
2021, May 25
THE TENTH EDITION OF THE ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH HAS ANNOUNCED THE CALL FOR APPLICATIONS,
2021-05-06 13:12
RECORDATI: FIRST QUARTER 2021 RESULTS AND 2021-2023 THREE-YEAR PLAN APPROVED; 2023 REVENUE FORECAST BETWEEN €1,900 AND € 2,000 MILLION,
2021-04-28 09:37
RECORDATI TO PRESENT THE FIRST QUARTER 2021 RESULTS AND THE 2021-2023 STRATEGY AND OUTLOOK UPDATE,
2021-03-23 00:00
RECORDATI: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S ANNUAL MEETING REINFORCE THE EFFICACY AND SAFETY OF ISTURISA® (OSILODROSTAT) IN CUSHING’S DISEASE,
2021-04-22 12:22
RECORDATI: REGISTRATION WITH THE COMPANIES’ REGISTER OF THE MERGER DEED BY ABSORPTION OF ROSSINI INVESTIMENTI S.P.A. AND FIMEI S.P.A. INTO RECORDATI S.P.A. COMPLETED,
2021-04-22 11:25
RECORDATI: PUBLIC DISCLOSURE (SUMMARY REPORT OF THE VOTES - ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 20.04.2021)
2021, April 21
Press release (on "il Sole 24 Ore") - 2020 final payment dividend,
2021-04-20 12:47
RECORDATI: SHAREHOLDERS APPROVE THE 2020 ACCOUNTS. DIVIDEND € 1.05 PER SHARE (+5.0% vs 2019).,
2021-04-12 18:13
RECORDATI: THE MERGER DEED RELATING TO THE MERGER BY ABSORPTION OF ROSSINI INVESTIMENTI S.P.A. AND FIMEI S.P.A. INTO RECORDATI S.P.A. HAS BEEN EXECUTED,
2021, March 30
Press release (on "il Sole 24 Ore") - Annual Financial Report, Non-Financial Statement and Corporate Governance 2020,
2021-03-29 18:12
RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 20.04.2021)
2021, March 25
RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS’ 20.04.2021)
2021, March 24
RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED IN JAPAN,
2021, March 20
Press release (on "il Sole 24 Ore") - Extract of the call notice of the Ordinary Shareholders meeting 20.04.2021,
2021-03-19 18:59
RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 20.04.2021)
2021-03-18 16:42
RECORDATI: BOARD APPROVES THE 2020 ACCOUNTS. SALES € 1,448.9 MILLION (-2.2%), EBITDA € 569.3 MILLION (+4.7%) ADJUSTED NET INCOME € 410.4 MILLION (+7.3%). 2020 DIVIDEND € 1.05 (+ 5.0 %),
2021-02-22 18:25
RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS,
2021-02-22 12:58
RECORDATI: PRELIMINARY 2020 RESULTS CONFIRM CONTINUED GROWTH OF OPERATING AND NET INCOME. EBITDA +4.7% AND ADJ NET INCOME +7.3%,
2021-01-29 18:06
RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE AND OTHER COUNTRIES,
2021, January 26
RECORDATI: CARBAGLU receives U.S. FDA Approval for a New Indication to Treat Acute Hyperammonemia Associated with Propionic Acidemia and Methylmalonic Acidemia
2020-12-29 11:10
Public disclosure
2020-12-18 12:41
Public disclosure
2020-12-17 18:04
RECORDATI: MERGER BY ABSORPTION OF ROSSINI INVESTIMENTI S.P.A. AND FIMEI S.P.A. INTO RECORDATI S.P.A. APPROVED BY THE EXTRAORDINARY SHAREHOLDERS’ MEETING,
2020-12-09 18:04
RECORDATI: TAX PETITION FOR THE FRUITION OF ACE TAX BENEFITS DERIVING FROM THE REVERSE MERGER OBTAINED POSITIVE ANSWER,
2020-11-30 18:04
RECORDATI: MARKET AUTHORIZATION APPLICATION FOR ARS-1 (EPINEPHRINE NASAL SPRAY) ACCEPTED BY EUROPEAN MEDICINES AGENCY,
2021-11-30 00:00
RECORDATI: 2021 CORPORATE EVENTS’ CALENDAR,
2020, November 14
Press release - (on "Milano Finanza") - Extract of the call notice of the extraordinary general meeting of the shareholders 17.12.2020,
2020-11-13 17:42
Call to an extraordinary general meeting of the shareholders 17.12.2020 (Reverse Merger),
2021-03-25 15:04
RECORDATI: PUBLICATION OF DOCUMENTATION RELATED TO THE REVERSE MERGER BY ABSORPTION OF ROSSINI INVESTIMENTI S.p.A. AND FIMEI S.p.A. INTO RECORDATI S.p.A.
2020, October 30
Press release (on "il Sole 24 Ore") - 2020 Interim Dividend Payment,
2020-10-29 13:11
RECORDATI: PROFIT GROWTH IN THE FIRST NINE MONTHS OF 2020. REVENUES -0.6%, EBITDA +7.1%, ADJUSTED NET INCOME +12.3%,
2020-10-07 15:15
RECORDATI: PUBLICATION OF THE INFORMATION DOCUMENT RELATING TO MAJOR TRANSACTIONS WITH RELATED PARTIES
2021-05-25 15:04
RECORDATI: FILING OF THE MERGER PLAN RELATING TO THE MERGER BY ABSORPTION OF ROSSINI INVESTIMENTI S.p.A. AND FIMEI S.p.A. INTO RECORDATI S.p.A.
2020-10-01 18:07
RECORDATI: RECORDATI: MERGER BY ABSORPTION OF FIMEI S.P.A. AND ROSSINI INVESTIMENTI S.P.A. INTO RECORDATI S.P.A. APPROVED,
2020-09-21 00:00
RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION,
2020-08-25 00:00
RECORDATI: U.S. FDA APPROVES CYSTADROPS® (Cysteamine Ophthalmic Solution) 0.37%, A NEW PRACTICAL TREATMENT OPTION FOR THE OCULAR MANIFESTATIONS OF CYSTINOSIS,
2020-08-03 17:06
Public disclosure compliance
2020, July 31
Press release (on "il Sole 24 Ore") - Interim Report First Half 2020,
2020-07-30 13:53
RECORDATI ANNOUNCES POSITIVE FIRST HALF 2020 RESULTS. REVENUES +2.3%, EBITDA +11.4%, ADJUSTED NET INCOME +16.8%,
2020-07-17 13:53
ISTURISA® IS NOW AVAILABLE AS A MEDICAL TREATMENT FOR CUSHING'S SYNDROME IN GERMANY,
2020-06-17 13:52
RECORDATI: ISTURISA® (OSILODROSTAT) PHASE III LINC-4 TRIAL MEETS ITS PRIMARY ENDPOINT IN CUSHING’S DISEASE,
2020, June 2
Recordati Rare Diseases announces first European launch of Isturisa® (osilodrostat),
2020-05-27 12:30
Public disclosure
2020, May 27
RECORDATI RARE DISEASES INC. ANNOUNCES AVALABILITY OF ISTURISA® (OSILODROSTAT) IN THE UNITED STATES,
2020-05-07 12:35
RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2020. REVENUES +12.1%, EBITDA +20.1%,
2020, April 30
Press release (on "il Sole 24 Ore") - 2019 final payment dividend,
2020-04-03 17:50
Public disclosure
2020-04-29 12:11
RECORDATI SHAREHOLDERS APPROVE THE 2019 ACCOUNTS. DIVIDEND € 1.00 PER SHARE (+8.7% vs 2018),
2020-04-17 18:15
RECORDATI: PROPOSAL OF CANDIDATES FOR THE OFFICE OF DIRECTORS AND THEIR RELATIVE REMUNERATION PRESENTED BY THE MAJORITY SHAREHOLDER FIMEI SpA IN RELATION TO ITEM 2 ON THE SHAREHOLDERS’ MEETING AGENDA
2020-04-08 10:46
Public disclosure
2020-04-08 18:54
RECORDATI: PUBLICATION OF THE LIST OF CANDIDATES FOR THE APPOINTMENT OF THE STATUTORY AUDITORS OF THE COMPANY
2020, April 8
Recordati Rare Diseases is now the European Marketing Authorization holder of Isturisa® (osilodrostat) indicated for Adult patients with Endogenous Cushing’s Syndrome,
2020-04-04 18:28
RECORDATI: NOTICE PURSUANT TO ART. 144-OCTIES, PARAGRAPH 2 OF ISSUERS’ REGULATIONS
2020-03-30 12:24
Public disclosure
2020, March 26
RECORDATI SUBMITS NEW DRUG APPLICATION FOR ISTURISA® IN JAPAN,
2020, March 25
Press release (on "il Sole 24 Ore") - 2019 financial statements and corporate governance report,
2020-03-24 17:36
Public Disclosure
2020, March 20
Press release (on "il Sole 24 Ore") - Extract of the call notice of the Ordinary Shareholders meeting 29.04.2020,
2020-03-19 17:56
Public disclosure
2020-03-18 14:11
BOARD APPROVES THE 2019 ACCOUNTS. SALES € 1,481.8 MILLION (+9.6%), EBITDA € 544.0 MILLION (+9.0%). 2019 DIVIDEND € 1.00 (+8.7%).,
2020, March 18
RECORDATI CONTRIBUTES TO SUPPORT HOSPITALS AND PATIENTS IN THE FACE OF THE EPIDEMIOLOGIC EMERGENCY DUE TO COVID-19,
2020-03-12 19:59
RECORDATI: LAUNCH OF A NEW SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS,
2020-03-09 08:32
RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED IN THE U.S.,
2020-02-17 19:29
RECORDATI: LAUNCH OF A SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS,
2020-02-14 14:04
RECORDATI: PRELIMINARY 2019 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITS. SALES +9.6%. EBITDA +9.0%.,
2020, February 4
RECORDATI: CHANGE IN 2020 CORPORATE EVENTS’ CALENDAR,
2020-01-15 12:01
RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED,
2019-11-15 17:24
RECORDATI: CHMP ADOPTS POSITIVE OPINION FOR ISTURISA® (OSILODROSTAT),
2019, November 12
RECORDATI: 2020 CORPORATE EVENTS' CALENDAR,
2019, November 1
Press release - 2019 Interim dividend payment,
2019-10-31 12:58
RECORDATI ANNOUNCES GROWTH IN THE FIRST NINE MONTHS 2019. REVENUES +8.6%, EBITDA +7.8%, OPERATING INCOME +4.9%, NET INCOME +6.6%. INTERIM DIVIDEND € 0.48 (+6.7%).,
2019, October 29
INAUGURAZIONE DEL PADIGLIONE GIOVANNI RECORDATI ALL'OSPEDALE DEI BAMBINI VITTORE BUZZI,
2019-10-23 12:03
RECORDATI: ACQUISITION OF WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699) COMPLETED,
2019, September 5
ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH AWARDED TO ALBERTO AURICCHIO,
2019-07-31 19:15
Public disclosure compliance
2019, July 31
Sole24Ore - Notice Interim Report First Half 2019,
2019-07-30 13:10
RECORDATI ANNOUNCES GROWTH IN THE FIRST HALF 2019. REVENUES +6.8%, EBITDA +7.4%, NET INCOME +6.1%,
2019-07-12 20:15
RECORDATI TO ACQUIRE WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699),
2019, June 24
RECORDATI RARE DISEASES, A WORLDWIDE LEADER IN RARE DISEASES AND ORPHAN DRUGS,
2019-05-08 12:24
RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2019. NEW THREE YEAR BUSINESS PLAN APPROVED,
2019-05-03 16:47
Public Disclosure Compliance
2019-04-15 19:07
Public Disclosure Compliance
2019-04-15 09:06
RECORDATI TO MEET WITH THE FINANCIAL COMMUNITY,
2019, April 12
Press Release - Notice on 2018 final payment dividend,
2019-04-11 14:38
RECORDATI SHAREHOLDERS APPROVE THE 2018 ACCOUNTS. DIVIDEND € 0.92 PER SHARE (+8.2% vs 2017),
2019-03-20 18:57
Public Disclosure
2019-03-12 18:23
Public Disclosure
2019-03-08 10:45
Public Disclosure
2019, March 5
Sole24Ore - Extract of the call notice of the Ordinary Shareholders meeting - 11.04.2019,
2019, March 5
Press release - Notice of filing of 2018 Annual Report and Corporate Governance,
2019-03-05 19:23
Public Disclosure
2019-03-04 18:18
Public Disclosure
2019-02-28 15:08
RECORDATI: BOARD APPROVES THE 2018 ACCOUNTS. SALES € 1,352.2 MILLION (+5.0%), EBITDA € 499.1 MILLION (+9.8%), OPERATING INCOME € 442.2 MILLION (+8.8%) AND NET INCOME € 312.4 MILLION (+8.2%). 2018 DIVIDEND € 0.92 (+8.2%),
2019-02-11 12:54
RECORDATI: PRELIMINARY 2018 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITABILITY. SALES +5.0%, EBITDA +9.8%, OPERATING INCOME +8.8%, NET INCOME +8.2%.,
2019, February 6
Public Disclosure Compliance
2019, February 6
RECORDATI OBTAINS EXCLUSIVE LICENSE FOR JUXTAPID® IN JAPAN,
2019, February 5
RECORDATI: SHAREHOLDERS APPOINT THE NEW BOARD OF DIRECTORS. THE BOARD OF DIRECTORS APPOINTS FLEMMING ØRNSKOV AS CHAIRMAN AND CONFIRMS ANDREA RECORDATI AS CHIEF EXECUTIVE OFFICER,
2019, February 1
RECORDATI: TERMINATION BY MUTUAL AGREEMENT OF THE EMPLOYMENT RELATIONSHIP WITH ALBERTO RECORDATI
2019, January 28
RECORDATI: 2019 CORPORATE EVENTS' CALENDAR,
2019-01-11 17:30
RECORDATI: PUBLICATION OF THE SLATE OF CANDIDATES FOR THE APPOINTMENT OF DIRECTOR OF THE COMPANY BY A GROUP OF ASSET MANAGEMENT COMPANIES AND INSTITUTIONAL INVESTORS
2019-01-07 14:54
RECORDATI: PUBLICATION OF THE SLATE OF CANDIDATES FOR THE APPOINTMENT OF DIRECTOR OF THE COMPANY BY FIMEI S.P.A
2019, January 7
Press release on behalf of FIMEI S.p.A. - New Recordati Board members proposed by majority shareholder FIMEI, including Dr. Flemming Ørnskov as Chairman designate
2019, January 7
Press release on behalf of FIMEI S.p.A. - New Recordati Board members proposed by majority shareholder FIMEI, including Dr. Flemming Ørnskov as Chairman designate
2018, December 31
RECORDATI CLOSES ACQUISITION OF TONIPHARM S.A.S. IN FRANCE
2018-12-21 16:38
RECORDATI: EXPECTATIONS FOR 2018 CONFIRMED AND 2019 OBJECTIVES ANNOUNCED; APPROVAL OF THE ISSUER’S NOTICE PURSUANT TO ART. 103 PARA. 3 OF ITALIAN LEGISLATIVE DECREE 58/1998, WITH REFERENCE TO THE PUBLIC MANDATORY TENDER OFFER FOR THE TOTAL NUMBER OF ORDINARY SHARES OF RECORDATI S.P.A.
2018, December 21
RECORDATI ACQUIRES TONIPHARM S.A.S. IN FRANCE
2018, December 20
Sole24Ore: Call notice of the Ordinary Shareholders Meeting 5 February 2019,
2018, December 20
RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA®
2018-12-19 19:41
Public Disclosure
2018-12-12 20:13
Shareholders Agreements
2018-12-11 19:18
Publication of the abstract of the Shareholders' Agreements
2018-12-06 18:01
RECORDATI: RESIGNATION OF BOARD MEMBERS; CO-OPTION OF THREE NEW DIRECTORS; APPOINTMENT OF CHAIRMAN; AN ORDINARY GENERAL MEETING OF THE SHAREHOLDERS IS CONVENED TO APPOINT A NEW BOARD OF DIRECTORS
2018, December 5
RECORDATI RECEIVES ORPHAN DRUG DESIGNATION FOR ITS INVESTIGATIONAL TREATMENT FOR NEUROTROPHIC KERATITIS
2018, November 5
RECORDATI RECEIVES ORPHAN DRUG DESIGNATION FOR ITS INVESTIGATIONAL TREATMENT FOR MSUD
2018, October 31
Notice: 2018 interim dividend payment,
2018-10-30 13:21
RECORDATI ANNOUNCES SALES AND MARGIN GROWTH IN THE FIRST NINE MONTHS 2018. REVENUES +5.1%, EBITDA +11.1%, OPERATING INCOME +9.6%, NET INCOME +8.2%. INTERIM DIVIDEND € 0.45 (+7.1%)
2018, September 12
THE NINTH EDITION OF THE INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH ARRIGO RECORDATI HAS ANNOUNCED THE CALL FOR NOMINATIONS
2018-08-03 15:08
Stock Options Granted
2018, July 28
Sole 24Ore: Notice Interim Report First Half 2018,
2018-07-26 12:24
RECORDATI ANNOUNCES SALES AND MARGIN GROWTH IN THE FIRST HALF 2018. REVENUES +6.9%, OPERATING INCOME +14.1%, NET INCOME +11.7%
2018-07-04 21:38
Shareholders Agreements
2018, July 4
SHAREHOLDERS AGREEMENTS,
2018-07-02 18:01
CVC AGREES TO ACQUIRE FIMEI S.P.A.
2018-06-29 20:10
CVC AGREES TO ACQUIRE FIMEI S.P.A.
2018, June 29
CVC Fund VII Acquires Controlling Stake in Recordati S.p.A.
2018, June 11
RECORDATI ACQUIRES NATURAL POINT S.R.L. IN ITALY
2018-05-09 15:48
Public Disclosure Compliance (shareholders' meeting minutes dated 18.04.18)
2018-05-08 11:25
RECORDATI ANNOUNCES SALES AND MARGIN GROWTH IN THE FIRST QUARTER 2018. REVENUES +7.2%, OPERATING INCOME +12.4%, NET INCOME +10.3%
2018, April 19
Sole24Ore - Notice of final dividend payment,
2018, April 18
Public Disclosure Compliance
2018, April 9
RECORDATI ACQUIRES INTERNATIONAL RIGHTS TO CYSTAGON® FROM MYLAN
2018-04-08 12:47
RECORDATI: SHAREHOLDERS APPROVE THE 2017 ACCOUNTS. DIVIDEND € 0.85 PER SHARE (+21.4% vs 2016)
2018-03-27 19:45
Public disclosure compliance
2018-03-19 17:23
Pubblic Disclosure
2018, March 16
Sole24Ore - Call notice of the Ordinary Shareholders meeting - 18.04.2018,
2018-03-16 19:18
Public Disclosure
2018, March 16
Sole24Ore - Notice of filing of 2017 Annual Report and Corporate Governance,
2018-03-15 12:14
RECORDATI: BOARD APPROVES THE 2017 ACCOUNTS. SALES € 1,288.1 MILLION (+11.6%), OPERATING INCOME € 406.5 MILLION (+24.1%) AND NET INCOME € 288.8 MILLION (+21.6%). 2017 DIVIDEND € 0.85 (+21.4%)
2018-02-08 12:23
RECORDATI: PRELIMINARY 2017 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITABILITY. SALES +11.6%, OPERATING INCOME +24.1%, NET INCOME +21.6%
2017, December 18
RECORDATI ACQUIRES TRANSIPEG®, TRANSIPEGLIB® AND COLOPEG® FOR THE FRENCH MARKET,
2017, November 29
RECORDATI: 2018 CORPORATE EVENTS' CALENDAR,
2017, October 27
Notice: 2017 INTERIM DIVIDEND PAYMENT,
2017-10-26 11:51
RECORDATI: EXCELLENT RESULTS IN THE FIRST NINE MONTHS 2017. CONTINUED GROWTH IN SALES +11.8%, OPERATING INCOME +21.8%, NET INCOME +20.6%. INTERIM DIVIDEND € 0.42 (+20%),
2017, July 28
Notice - Half Yearly Financial Report at 30 June 2017,
2017-07-27 11:14
RECORDATI: VERY GOOD RESULTS AGAIN IN THE FIRST HALF 2017. CONTINUED GROWTH IN SALES +10.7%, OPERATING INCOME +19.4%, NET INCOME +19.8%.,
2017-07-19 18:13
RECORDATI: THE EUROPEAN COMMISSION APPROVES REAGILA® (CARIPRAZINE) FOR THE TREATMENT OF SCHIZOPHRENIA,
2017, July 7
Recordati Rare Diseases Introduces New PANHEMATIN® (Hemin for Injection) Dosage Strength for Treatment of Acute Intermittent Porphyria (AIP),
2017-07-03 08:01
RECORDATI: ACQUISITION OF RIGHTS TO ASTRAZENECA'S METOPROLOL BASED TREATMENTS IN EUROPE COMPLETED,
2017, June 16
RECORDATI LICENSES AN INNOVATIVE TREATMENT FOR NEUROTROPHIC KERATITIS,
2017-05-22 08:01
RECORDATI ACQUIRES RIGHTS TO ASTRAZENECA’S METOPROLOL BASED TREATMENTS IN EUROPE,
2017, May 19
European CHMP Issues Positive Opinion for Cariprazine for the Treatment of Schizophrenia,
2017-05-10 19:13
Public disclosure compliance,
2017-05-04 12:49
RECORDATI: EXCELLENT RESULTS IN THE FIRST QUARTER 2017. CONTINUED GROWTH IN SALES +13.1%, OPERATING INCOME +19.0%, NET INCOME +19.9%,
2017-04-19 00:00
Recordati establishes Canadian presence with launch of Recordati Rare Diseases Canada Inc.,
2017-04-13 00:00
Recordati Rare Diseases Inc. Acquires North American Marketing Rights to CYSTADANE®,
2017, April 12
Notice of 2016 final dividend payment,
2017-04-11 14:11
RECORDATI: SHAREHOLDERS APPROVE THE 2016 ACCOUNTS. DIVIDEND € 0.70 PER SHARE (+16.7% vs 2015),
2017-04-07 18:35
BoD resolution approving the merger registered with Companies Register
2017-04-05 11:03
BoD approves the merger of Recordati SA Chemical and Pharmaceutical Company in Recordati SPA
2017-03-20 19:09
RECORDATI: PUBLICATION OF LISTS OF CANDIDATES FOR THE APPOINTMENT OF DIRECTOR AND STATUTORY AUDITOR OF THE COMPANY
2017-03-17 16:56
Public disclosure
2017-03-17 18:19
RECORDATI: NOTICE PURSUANT TO ART. 144-OCTIES, PARAGRAPH 2 OF ISSUERS’ REGULATIONS
2017-03-19 17:47
Public disclosure
2017, March 2
Notice of filing of 2016 Annual Report and merger notice to shareholders,
2017-03-01 12:38
RECORDATI: BOARD APPROVES THE 2016 ACCOUNTS. SALES € 1,153.9 MILLION (+10.1%), OPERATING INCOME € 327.4 MILLION (+17.6%) AND NET INCOME € 237.4 MILLION (+19.4%). 2016 DIVIDEND € 0.70 (+16.7%),
2017-03-01 17:40
Call notice of Ordinary and Extraordinary Shareholders Meeting 11 April 2017,
2017-03-01 19:26
Public disclosure
2017-02-27 12:59
RECORDATI: SIGNS AN EXCLUSIVE LICENSE AGREEMENT WITH THE MEYER HOSPITAL IN FLORENCE,
2017-02-09 12:23
RECORDATI: PRELIMINARY 2016 RESULTS CONFIRM CONTINUED GROWTH OF REVENUES AND PROFITABILITY. NEW THREE YEAR BUSINESS PLAN PRESENTED,
2017-02-01 08:35
RECORDATI TO MEET WITH THE FINANCIAL COMMUNITY AND SPECIALIZED PRESS IN MILAN,
2017, January 27
RECORDATI ANNOUNCES MARKETING APPROVAL FOR CYSTADROPS®,
2016, December 14
UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM
2016, December 14
RECORDATI: 2017 CORPORATE EVENTS’ CALENDAR and DISCLOSURE OF QUARTERLY REPORTS,
2016, December 6
UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM
2016, December 1
UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM
2016, November 24
UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM
2016, November 17
UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM
2016, November 15
ERYTECH ANNOUNCES WITHDRAWAL OF ITS EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR GRASPA FOR ACUTE LYMPHOBASTIC LEUKEMIA AND PREPARES FOR RESUBMISSION,
2016, November 10
UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM
2016, October 28
Notice: 2016 INTERIM DIVIDEND PAYMENT,
2016, October 27
RECORDATI: EXCELLENT RESULTS IN THE FIRST NINE MONTHS 2016. CONTINUED GROWTH IN SALES +9.9%, OPERATING INCOME +18.5%, NET INCOME +19.5%,
2016, October 2
Recordati initiates a share buy-back program
2016, August 16
RECORDATI ANNOUNCES THAT ITS CHAIRMAN AND CEO GIOVANNI RECORDATI PASSED AWAY,
2016, August 16
RECORDATI: ALBERTO RECORDATI APPOINTED CHAIRMAN; ANDREA RECORDATI APPOINTED VICE CHAIRMAN AND CHIEF EXECUTIVE OFFICER,
2016, August 2
RECORDATI AND RICHTER SIGNED A LICENSE AGREEMENT FOR MARKETING CARIPRAZINE IN WESTERN EUROPE,
2016, July 29
Notice - Half Yearly Financial Report at 30 June 2016,
2016, July 28
RECORDATI: EXCELLENT RESULTS IN THE FIRST HALF 2016. CONTINUED GROWTH IN SALES +9.1%, OPERATING INCOME +17.2%, NET INCOME +18.9%,
2016, July 14
RECORDATI ACQUIRES THE SWISS PHARMACEUTICAL COMPANY PRO FARMA,
2016, May 31
RECORDATI ACQUIRES THE ITALIAN PHARMACEUTICAL COMPANY ITALCHIMICI,
2016, May 5
RECORDATI: EXCELLENT RESULTS IN THE FIRST QUARTER 2016. SALES +9.6%, OPERATING INCOME +22.7%, NET INCOME +26.0%,
2016, May 2
Public Disclosure - Minutes SHM 13.4.2016
2016, April 14
Notice of 2015 final dividend payment,
2016, April 13
RECORDATI SHAREHOLDERS APPROVE THE 2015 ACCOUNTS. DIVIDEND € 0.60 PER SHARE (+20.0% vs 2014),
2016, March 21
PUBLIC DISCLOSURE
2016, March 15
PUBLIC DISCLOSURE
2016, March 9
Notice of filing of the 2015 Annual Report,
2016, March 8
SHGM Call notice 13 April 2016,
2016, March 8
RECORDATI: BOARD APPROVES THE 2015 ACCOUNTS. SALES € 1,047.7 MILLION (+6.1%), OPERATING INCOME € 278.5 MILLION (+20.6%) AND NET INCOME € 198.8 MILLION (+23.3%). 2015 DIVIDEND € 0.60 (+20.0%),
2016, February 29
RARE DISEASE DAY,
2016, February 12
Update on the execution of the share buy-back program
2016, February 11
RECORDATI PRELIMINARY 2015 RESULTS: REVENUE GROWTH AND FURTHER MARGIN IMPROVEMENT, SALES +6.1%, OPERATING INCOME +20.6% AND NET INCOME +23.3%
2015, November 20
2016 Corporate events' calendar,
2015, October 29
First nine months 2015 and 2015 interim dividend payment 2015,
2015, October 28
RECORDATI REPORTS SALES +5.7%, OPERATING INCOME +18.1% AND NET INCOME +23.0% IN THE FIRST NINE MONTHS 2015. THE INTERNATIONAL BUSINESS GROWS BY 8.8%,
2015, October 15
Update on the execution of the share buy-back program
2015, October 6
Update on the execution of the share buy-back program
2015, September 14
ERYTECH submits EMA Marketing Authorization,
2015, September 8
ORPHAN EUROPE Announces that Health Canada has Granted Market Authorization for Carbaglu® (carglumic acid),
2015, July 30
Notice of filing of yearly financial report 2015 of filing - half - yearly financial report 2015,
2015, July 29
RECORDATI REPORTS SALES +6.2%, OPERATING INCOME +19.2% AND NET INCOME +24.3% IN THE FIRST HALF 2015 THANKS TO ITS INTERNATIONAL BUSINESS,
2015, June 13
ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH AWARDED TO JOHN J. V. MCMURRAY AND SALIM YUSUF,
2015, May 15
Update on the execution of the share buy-back program
2015, May 6
Notice of filing of First Quarter 2015,
2015, May 5
RECORDATI: SALES GROWTH AND FURTHER MARGIN IMPROVEMENT IN THE FIRST QUARTER 2015. SALES +5.9%, OPERATING INCOME +18.1%, NET INCOME +21.5%,
2015, April 30
Public disclosure compliance - Minutes of the Shareholders' meeting 15.4.2015
2015, April 30
Recordati initiates a share buy-back program
2015, April 16
Notice of 2014 final dividend payment,
2015-04-15 18:07
RECORDATI: RECORDATI SHAREHOLDERS APPROVE THE 2014 ACCOUNTS. DIVIDEND € 0.50 PER SHARE (+51.5% vs 2013),
2015, March 18
Public Disclosure Compliance
2015, March 5
Avviso integrale di convocazione dell’Assemblea degli Azionisti del 15 aprile 2015,
2015, March 5
SHGM Call notice,
2015, March 5
Notice of filing of the 2014 Annual Report,
2015, March 4
RECORDATI; BOARD APPROVES THE 2014 ACCOUNTS. REVENUES € 987.4 MILLION (+4.9%), OPERATING INCOME € 231.0 MILLION (+18.2%), NET INCOME € 161.2 MILLION (+20.6%). 2014 DIVIDEND € 0.50 (+51.5%),
2015-02-12 12:03
RECORDATI: PRELIMINARY 2014 RESULTS: REVENUE GROWTH AND SIGNIFICANT MARGIN IMPROVEMENT, SALES +4.9%, OPERATING INCOME +18.2% AND NET INCOME +20.6%,
2015, January 16
RECORDATI: CHANGE TO 2015 CORPORATE EVENTS CALENDAR
2014, November 28
Recordati: 2015 Corporate Events’ Calendar,
2014, October 28
Notice of filing of First nine months 2014,
2014, October 28
Revenue growth and significant margin improvement in first nine months 2014 results. Sales +5.7%, operating income +21.6% and net income +22.2%,
2014, October 9
Recordati initiates a share buy-back program,
2014, September 30
ERYTECH reports positive top-line Phase III results from clinical study with GRASPA® in Acute Lymphoblastic Leukemia,
2014, September 22
Recordati: public disclosure compliance
2014, September 16
Recordati obtains license to new treatment for premature ejaculation from Plethora,
2014, August 30
The eighth edition of the Arrigo Recordati International Prize for Scientific Research issues the call for nominations,
2014, August 1
Recordati: public disclosure compliance
2014, July 29
Notice of filing of First Half 2014,
2014, July 29
Recordati reports excellent results in the first half 2014. Sales +6.3%, operating income +18.8% and net income +18.1,
2014, July 3
Recordati: Carbaglu® receives orphan drug designation in the U.S. For organic acidemias,
2014, May 26
Recordati finalizes the second tranche of its acquisition of Opalia Pharma in Tunisia,
2014-04-17 14:11
Recordati: Shareholders approve the 2013 accounts. Dividend € 0.33 per share.,
2014, May 9
Recordati: public disclosure compliance
2014, May 6
Notice of filing of First Quarter 2014,
2014-05-06 07:33
Recordati: sales growth and significant margin improvement in the first quarter 2014 (sales +6.5%, operating income +18.1%, net income +13.2%),
2014, April 18
Notice of 2013 final dividend payment,
2014, April 11
Recordati receives the special Award "Finance for Growth",
2014, March 27
Recordati: publication of lists of candidates for the appointment of Directors and Statutory Auditors of the company
2014, March 24
Recordati: notice pursuant to art. 144-octies, paragraph 2 of issuers' regulations
2014, March 21
Recordati: public disclosure compliance
2014, March 14
Recordati: public disclosure compliance
2014, March 7
Notice of filing of the 2013 Annual Report,
2014, March 6
Recordati: Board approves the2013 accounts. Revenue € 941.6 million (+13.7%), operating income € 195.4 million (+17.0%), net income € 133.7 million (+12.8%). 2013 dividend € 0.33 (+10.0%),
2014, February 26
The European Organisation for Rare Diseases awards Orphan Europe for exceptional contribution to reducing the impact of rare diseases on people's lives,
2014, February 11
Recordati: preliminary 2013 results show significant growth. Sales +13.7%, EBIT +17.0%, net income +12.8%. A productive year for investments,
2014, February 10
Recordati obtains Vitaros® license from Apricus Biosciences,
2014, January 16
Recordati Board of Directors approves 2014 objectives
2013, December 17
Recordati: 2014 corporate events' calendar,
2013, October 31
Interim Report - First nine months 2013 and 2013 interim dividend payment,
2013, October 31
Recordati finalizes the first tranche of its acquisition of Opalia Pharma in Tunisia,
2013, October 30
Recordati reports significant growth in the first nine months 2013. Sales +13.2%, operating income +12.0% and net income +9.0%. Interim dividend € 0.22 per share,
2013, October 21
Recordati finalizes its acquisition of Laboratorios Casen Fleet in Spain,
2013, September 23
Recordati: Andrea Recordati appointed Chief Operating Officer (COO),
2013, September 17
Recordati: update on the execution of the share buy-back program
2013, September 9
Recordati acquires the Spanish pharmaceutical company Laboratorios Casen Fleet,
2013, September 6
Recordati: update on the execution of the share buy-back program
2013, July 26
Notice of filing of First Half 2013,
2013, July 25
Recordati reports excellent results in the first half 2013. Sales +13.8%, operating income +13.8% and net income +11.1%,
2013, July 24
Recordati: update on the execution of the share buy-back program
2013, July 24
Recordati acquires the Tunisian pharmaceutical company Opalia Pharma,
2013, July 3
Recordati: update on the execution of the share buy-back program
2013, June 24
Recordati: update on the execution of the share buy-back program
2013, June 15
Arrigo Recordati International Prize for Scientific Research awarded to Filippo Crea,
2013, June 14
Recordati: update on the execution of the share buy-back program
2013, June 6
Recordati: update on the execution of the share buy-back program
2013, May 29
Recordati: update on the execution of the share buy-back program
2013, May 21
Recordati: update on the execution of the share buy-back program
2013, May 10
Notice of filing of First Quarter 2013,
2013-05-09 12:01
Recordati: initiates a share buy-back program,
2013, May 9
Recordati: significant sales and earnings growth in the first quarter 2013 (sales +11.4%, net income +11.8%) thanks to the international business (+16.1%),
2013, May 7
Recordati: Public disclosure compliance - Minutes SHGM 17.4.2013
2013, April 18
Notice of 2012 final dividend payment,
2013, April 17
Recordati: shareholders approve the 2012 accounts. Dividend € 0.30 per share,
2013, March 22
Recordati: public disclosure compliance - Publication Remuneration report
2013, March 15
Recordat: public disclosure compliance – Publications of the Directors’ reports
2013, March 15
Shareholders' Meeting Call Notice,
2013, March 15
Shareholders' Meeting Call Notice,
2013, March 14
Recordati: Board approves a supplement to the agenda of the annual meeting of shareholders
2013, March 14
Recordati: public disclosure compliance
2013, March 8
Notice of filing of the 2012 Annual Report,
2013, March 7
Recordati: Board approves the 2012 accounts. Revenue € 828.3 million (+8.7%), operating income € 167.0 million (+2.1%), net income € 118.5 million (+1.8%). 2012 dividend € 0.30,
2013, February 12
Recordati: positive preliminary 2012 results. Sales +8.7%, EBIT +2.1%, net income +1.8%. A productive year for investments,
2013-02-04 08:35
Recordati to meet with the financial community and specialized press in Milan,
2013, January 31
Recordati: update on the execution of the share buy-back program
2013, January 21
Recordati finalizes its acquisition of a portfolio of products in the USA
2012, May 8
Recordati: good first quarter 2012 results (revenue +11.0%, net income +7.5%) thanks to the growth of the international business (+14.5%),